Relay Therapeutics (RLAY) AI Stock Analysis

• Market Cap: $461.10M
• Dividend Yield: N/A
• Average Volume (3M): 2.35M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.47
• Revenue Growth: -60.83%
• EPS Growth: 14.13%
• Country: US
• Employees: 261
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -2.40
• Shares Outstanding: 169,521,850
• 10 Day Avg. Volume: 2,680,345
• 30 Day Avg. Volume: 2,346,651
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 51.84
• Price to Cash Flow (P/CF): -2.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $17.00
• Price Target Upside: 525.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

Relay Therapeutics has a low stock score due to significant challenges in achieving profitability and cash flow generation, reflected in its financial performance. The technical analysis shows a bearish trend with weak momentum indicators, and the valuation is unfavorable due to ongoing losses. While recent corporate events highlight progress in drug development, these have not yet materially impacted the stock's financial outlook.

Positive Factors

Clinical Trials and Efficacy

The combination of RLY-2608 and Faslodex achieved a 38.7% objective response rate in patients with PIK3CA-mutant, HR+/HER2- metastatic breast cancer, indicating promising efficacy.

Partnerships and Collaborations

Scorpion has a collaboration with Pfizer to evaluate the triplet combination of STX-478 + atirmociclib + fulvestrant in frontline patients with PI3Kα-mutated HR +/HER2- metastatic breast cancer.

Negative Factors

Pipeline Delays

The initiation of clinical trials for the NRAS and Fabry programs will be delayed to optimize resource allocation.

Price Target Adjustment

The launch dates for RLY-2608 have been delayed, which lowers the price target to $12 from $21.

Relay Therapeutics Business Overview & Revenue Model

Company Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Relay Therapeutics generates revenue primarily through collaboration and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of drugs. Additionally, the company invests in developing its proprietary drug candidates, which could lead to future revenues upon regulatory approval and market launch. Strategic partnerships and licensing deals are pivotal to Relay Therapeutics’ revenue model, allowing them to capitalize on their innovative drug discovery platform.

Relay Therapeutics Financial Statement Overview

Summary

Relay Therapeutics faces ongoing challenges in achieving profitability and positive cash flow. While the balance sheet remains stable with low leverage, the income statement reveals significant losses and operational challenges. The cash flow statement highlights the difficulty in generating sustainable cash flows. Overall, while there are strengths in equity financing and asset management, profitability and cash generation remain critical concerns.

Income Statement

Relay Therapeutics has experienced volatility in revenue, with significant fluctuations over the years. The gross profit margin is positive in recent years, but the company consistently reports negative net income, resulting in a negative net profit margin. EBIT and EBITDA margins are also negative, indicating operational challenges. The revenue has shown growth over the past year, but the overall trajectory remains uncertain.

Balance Sheet

The balance sheet of Relay Therapeutics is relatively strong with a high equity ratio, indicating a larger proportion of assets financed by equity. The company has a low debt-to-equity ratio, suggesting manageable leverage. However, the consistent net losses impact the return on equity negatively. Overall, the company maintains a stable financial position despite ongoing losses.

Cash Flow

Relay Therapeutics has faced challenges generating positive cash flow, with negative free and operating cash flows. The free cash flow has been declining, indicating cash constraints. The operating cash flow to net income ratio is negative, reflecting inefficiencies in converting profits to cash. While the company has been able to access financing, it remains cash flow negative.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.02M	10.01M	25.55M	1.38M	3.03M	82.65M
	Gross Profit
-104.66M	10.01M	20.28M	-2.75M	-896.00K	79.11M
	EBIT
-268.98M	-372.47M	-373.00M	-299.27M	-364.70M	-55.80M
	EBITDA
-267.40M	-380.21M	-374.15M	-306.82M	-222.18M	-52.25M
	Net Income Common Stockholders
-256.56M	-337.71M	-341.97M	-254.26M	-496.81M	-49.01M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
781.32M	781.32M	750.09M	998.92M	958.07M	678.06M
	Total Assets
871.30M	871.30M	843.98M	1.10B	1.01B	799.83M
	Total Debt
48.50M	48.50M	53.47M	57.74M	22.90M	24.42M
	Net Debt
-75.78M	-75.78M	-90.27M	-941.17M	-935.17M	-423.22M
	Total Liabilities
93.50M	93.50M	91.98M	149.55M	110.64M	36.54M
	Stockholders Equity
777.79M	777.79M	752.00M	950.22M	897.81M	763.29M
Cash Flow		Free Cash Flow
-206.44M	-251.13M	-304.44M	-238.55M	-77.88M	-104.42M
	Operating Cash Flow
-199.17M	-249.11M	-300.32M	-229.49M	-74.41M	-102.49M
	Investing Cash Flow
-340.95M	-41.08M	257.63M	-188.75M	-479.51M	81.67M
	Financing Cash Flow
387.79M	270.15M	34.75M	289.91M	388.09M	426.51M

Relay Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RLAY, the sentiment is Negative. The current price of 2.72 is below the 20-day moving average (MA) of 3.26, below the 50-day MA of 3.85, and below the 200-day MA of 5.75, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 33.65 is Neutral, neither overbought nor oversold. The STOCH value of 8.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RLAY.

Relay Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	80 Outperform	$10.27B	20.71	23.13%	―	18.49%	176.71%
INCY	66 Neutral	$11.73B	223.45	0.76%	―	14.76%	-88.32%
VRTX	64 Neutral	$126.52B	―	-3.15%	―	11.64%	-114.72%
BPMC	52 Neutral	$5.67B	―	-31.26%	―	104.04%	87.80%
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	17.48%	1.17%
RLAY	46 Neutral	$461.10M	―	-44.15%	―	-60.83%	14.13%
FATE	42 Neutral	$97.33M	―	-54.21%	―	-78.55%	-0.92%

Relay Therapeutics Corporate Events

Relay Therapeutics Highlights Progress at Healthcare Conference

Relay Therapeutics announced participation in the 43rd Annual J.P. Morgan Healthcare Conference, highlighting progress in their clinical programs, notably the RLY-2608, aimed at breast cancer. The company anticipates starting pivotal trials and clinical data updates in 2025, supported by a strong financial position and extensive global clinical experience, targeting significant market opportunities in the oncology sector.